New combo therapy aims to slow advanced GIST
NCT ID NCT05208047
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the experimental drug CGT9486 to the standard drug sunitinib helps people with advanced GIST live longer without their cancer growing. About 482 adults with GIST that cannot be removed by surgery or has spread will take part. The goal is to see if the combination works better than sunitinib alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 482 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2022
- Expected to finish
-
Jan 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: 1. Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required) 2. Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy) 3. Subjects must have received the following treatment: * DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST * Part 1b: Treatment with ≥2 prior TKI for GISTs * Part 2: Prior treatment with imatinib only * GIST 1L Substudy: No prior systemic therapy for GIST including adjuvant therapy. Exception: up to 10 subjects with ongoing imatinib therapy of ≤4 weeks 4. Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy) 5. Eastern Cooperative Oncology Group (ECOG) Status * 0 to 2 (Part 1a, Part 1b, Part 2, DDI Substudy) * 0 to 1 (GIST 1L Substudy) 6. Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits Key Exclusion Criteria: 1. Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency (Part 1a, Part 1b, Part 2, DDI Substudy) 2. Clinically significant cardiac disease 3. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug (Part 1a, Part 1b, Part 2, DDI Substudy) 4. Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption 5. Any active bleeding excluding hemorrhoidal or gum bleeding 6. Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody. 7. Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening 8. Received strong CYP3A4 inhibitors or inducers (Part 1a, Part 1b, Part 2, DDI Substudy) 9. Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced gastrointestinal stromal tumors are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
8 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
AP-HM - Hôpital de la Timone
ACTIVE_NOT_RECRUITINGMarseille, 13005, France
-
ASST degli Spedali Civili di Brescia
ACTIVE_NOT_RECRUITINGBrescia, 25123, Italy
-
Aarhus University Hospital
ACTIVE_NOT_RECRUITINGAarhus, 8200, Denmark
-
Alberta Health Services Cross Cancer Institute
ACTIVE_NOT_RECRUITINGEdmonton, Alberta, T6G 1Z2, Canada
-
Asan Medical Center
ACTIVE_NOT_RECRUITINGSeoul, 05505, South Korea
-
Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
ACTIVE_NOT_RECRUITINGVerona, 31726, Italy
-
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
ACTIVE_NOT_RECRUITINGPalermo, 90127, Italy
-
Azienda Ospedaliero-Universitaria Careggi
ACTIVE_NOT_RECRUITINGFlorence, 50134, Italy
-
Bankstown-Lidcombe Hospital
ACTIVE_NOT_RECRUITINGBankstown, 2200, Australia
-
Beatson, West of Scotland Cancer Centre
WITHDRAWNGlasgow, G12 0YN, United Kingdom
-
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
ACTIVE_NOT_RECRUITINGSão Paulo, 09060-650, Brazil
-
CHU de Toulouse - Hospital Rangueil
ACTIVE_NOT_RECRUITINGToulouse, 31400, France
-
Cambridge Addenbrooke's Hospital
ACTIVE_NOT_RECRUITINGCambridge, CB2 0QQ, United Kingdom
-
Centre Eugene Marquis
ACTIVE_NOT_RECRUITINGRennes, 35042, France
-
Centre Leon Berard
ACTIVE_NOT_RECRUITINGLyon, 69008, France
-
Centre Oscar Lambret
ACTIVE_NOT_RECRUITINGLille, 59000, France
-
Centro Riferimento Oncologico - Aviano
ACTIVE_NOT_RECRUITINGAviano, 33081, Italy
-
Centro de Investigacion Medica Aquascalientes (CIMA)
WITHDRAWNAguascalientes, 20116, Mexico
-
Centro de Oncologia de Precision, Universidad Mayor
ACTIVE_NOT_RECRUITINGSantiago, 7560908, Chile
-
Centrum Onkologii im. Prof. Franciszka Lukaszczyka
WITHDRAWNBydgoszcz, 85-796, Poland
-
Chang Gung Memorial Hospital - Kaohsiung Branch
ACTIVE_NOT_RECRUITINGKaohsiung City, 83301, Taiwan
-
Chang Gung Memorial Hospital - Linkou Branch (CGMHLK)
ACTIVE_NOT_RECRUITINGTaoyuan, 33305, Taiwan
-
China Medical University Hospital
ACTIVE_NOT_RECRUITINGTaichung, 40447, Taiwan
-
City of Hope
ACTIVE_NOT_RECRUITINGDuarte, California, 91010, United States
-
Dana-Farber Cancer Institute
ACTIVE_NOT_RECRUITINGBoston, Massachusetts, 02115, United States
-
Debreceni Egyetem, Klinikai Központ, Onkológiai Klinika
ACTIVE_NOT_RECRUITINGDebrecen, 4032, Hungary
-
Duke University
ACTIVE_NOT_RECRUITINGDurham, North Carolina, 27705, United States
-
Erasmus MC
ACTIVE_NOT_RECRUITINGRotterdam, 3015 GD, Netherlands
-
Fakultni nemocnice Hradec Kralove
WITHDRAWNHradec Králové, 500 05, Czechia
-
Fakultni nemocnice Olomouc - Oncology clinic
ACTIVE_NOT_RECRUITINGOlomouc, 77900, Czechia
-
Fondazione IRCCS Istituto Nazionale dei Tumori
ACTIVE_NOT_RECRUITINGMilan, 20133, Italy
-
Fox Chase Cancer Center
ACTIVE_NOT_RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
-
Fred Hutchinson Cancer Center
ACTIVE_NOT_RECRUITINGSeattle, Washington, 98109, United States
-
Gustave Roussy
ACTIVE_NOT_RECRUITINGVillejuif, 94805, France
-
Guy's Hospital
WITHDRAWNLondon, SE1 9RT, United Kingdom
-
Haukeland University Hospital - Bergen
ACTIVE_NOT_RECRUITINGBergen, 5021, Norway
-
Helios Klinikum Bad Saarow
ACTIVE_NOT_RECRUITINGBad Saarow, 15526, Germany
-
Helios Klinikum Berlin-Buch
ACTIVE_NOT_RECRUITINGBerlin, 13125, Germany
-
Hong Kong United Oncology Centre
ACTIVE_NOT_RECRUITINGJordon, Hong Kong
-
Hospital Clinico San Carlos
ACTIVE_NOT_RECRUITINGMadrid, 28040, Spain
-
Hospital Clinico Universitario Virgen de la Arrixaca
WITHDRAWNEl Palmar, 30120, Spain
-
Hospital Clinico Universitario de Santiago de Compostela
ACTIVE_NOT_RECRUITINGSantiago de Compostela, 15706, Spain
-
Hospital Fundación Jiménez Díaz
ACTIVE_NOT_RECRUITINGMadrid, 28040, Spain
-
Hospital General Universitario Gregorio Maranon
ACTIVE_NOT_RECRUITINGMadrid, 28007, Spain
-
Hospital Universitario 12 de Octubre
ACTIVE_NOT_RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Miguel Servet
WITHDRAWNZaragoza, 50009, Spain
-
Hospital Universitario Vall d'Hebron
ACTIVE_NOT_RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario Virgen del Rocio
ACTIVE_NOT_RECRUITINGSeville, 41013, Spain
-
Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
ACTIVE_NOT_RECRUITINGCampinas, 130.83-888, Brazil
-
Hospital de la Santa Creu i Sant Pau Barcelona
WITHDRAWNBarcelona, 08041, Spain
-
Humanity & Health Clinical Trial Centre
WITHDRAWNCentral, Hong Kong
-
I Can Oncology Center SA De CV
ACTIVE_NOT_RECRUITINGMonterrey, 64710, Mexico
-
ICO St-Herblain
ACTIVE_NOT_RECRUITINGSaint-Herblain, 44800, France
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
ACTIVE_NOT_RECRUITINGBologna, 40138, Italy
-
IRCCS La Fondazione e l'Istituto di Candiolo
WITHDRAWNCandiolo, 10060, Italy
-
Institut Bergonie
ACTIVE_NOT_RECRUITINGBordeaux, 33076, France
-
Institut Catala d'Oncologia - L'Hospitalet
ACTIVE_NOT_RECRUITINGBarcelona, 08908, Spain
-
Instituto Alexander Fleming
ACTIVE_NOT_RECRUITINGBuenos Aires, C1426ANZ, Argentina
-
Instituto Oncologico FALP
ACTIVE_NOT_RECRUITINGSantiago, 7500921, Chile
-
Instituto Oncologico de Cordoba (IONC)
ACTIVE_NOT_RECRUITINGCórdoba, X5000HWE, Argentina
-
Istituto Clinico Humanitas
ACTIVE_NOT_RECRUITINGRozzano, 20089, Italy
-
Istituto Europeo di Oncologia
ACTIVE_NOT_RECRUITINGMilan, 20141, Italy
-
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
ACTIVE_NOT_RECRUITINGMeldola, 47014, Italy
-
Karolinska University Hospital
ACTIVE_NOT_RECRUITINGSolna, 171 76, Sweden
-
Korea University Guro Hospital
ACTIVE_NOT_RECRUITINGSeoul, 08308, South Korea
-
Masarykuv onkologicky ustav
ACTIVE_NOT_RECRUITINGBrno, 65653, Czechia
-
Mayo Clinic
ACTIVE_NOT_RECRUITINGScottsdale, Arizona, 85259, United States
-
Mayo Clinic
ACTIVE_NOT_RECRUITINGRochester, Minnesota, 55905, United States
-
Mayo Clinic Jacksonville
ACTIVE_NOT_RECRUITINGJacksonville, Florida, 32224, United States
-
MedStar Washington Hospital Center
RECRUITINGWashington D.C., District of Columbia, 20010, United States
-
Medizinische Hochschule Hannover- Urology Oncology
ACTIVE_NOT_RECRUITINGHanover, 30625, Germany
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
-
Mid Florida Hematology and Oncology Center
WITHDRAWNOrange City, Florida, 32763, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
ACTIVE_NOT_RECRUITINGWarsaw, 02-781, Poland
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej
ACTIVE_NOT_RECRUITINGGliwice, 44-102, Poland
-
National Cancer Center
WITHDRAWNGoyang-si, Gyeonggi-do, 10408, South Korea
-
National Taiwan University Hospital
ACTIVE_NOT_RECRUITINGNew Taipei City, 10002, Taiwan
-
Nebraska Methodist Hospital
RECRUITINGOmaha, Nebraska, 68114, United States
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
ACTIVE_NOT_RECRUITINGAmsterdam, 1066 CX, Netherlands
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
-
Oaxaca Site Management Organization S.C.
WITHDRAWNOaxaca City, 68000, Mexico
-
Oregon Health & Science University (OHSU)
ACTIVE_NOT_RECRUITINGPortland, Oregon, 97239, United States
-
Orlando Health Cancer Institute
RECRUITINGOrlando, Florida, 32806, United States
-
Oslo University Hospital
ACTIVE_NOT_RECRUITINGOslo, 0310, Norway
-
Policlinico Universitario Campus Bio-Medico
ACTIVE_NOT_RECRUITINGRoma, 00128, Italy
-
Prince of Wales Hospital
ACTIVE_NOT_RECRUITINGShatin, Hong Kong
-
Princess Margaret Hospital
ACTIVE_NOT_RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Roswell Park Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGBuffalo, New York, 14203, United States
-
Royal Marsden Hospital - Surrey
ACTIVE_NOT_RECRUITINGLondon, SW3 6JJ, United Kingdom
-
Samsung Medical Center
ACTIVE_NOT_RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hosptial
ACTIVE_NOT_RECRUITINGSeoul, 03080, South Korea
-
Sheffield Teaching Hospitals NHS Foundation Trust
ACTIVE_NOT_RECRUITINGSheffield, S10 2SJ, United Kingdom
-
Sir Charles Gairdner Hospital
ACTIVE_NOT_RECRUITINGNedlands, Western Australia, 6009, Australia
-
Skane University Hospital Lund
ACTIVE_NOT_RECRUITINGLund, 22185, Sweden
-
Stichting Radboud Universitair Medisch Centrum
ACTIVE_NOT_RECRUITINGNijmegen, 6525 GA, Netherlands
-
Szpital Specjalistyczny w Brzozowie
ACTIVE_NOT_RECRUITINGBrzozów, 36-200, Poland
-
Taipei Veterans General Hospital (VGHTP)
ACTIVE_NOT_RECRUITINGTaipei, 11217, Taiwan
-
The Christie NHS Foundation Trust
ACTIVE_NOT_RECRUITINGManchester, M20 4BX, United Kingdom
-
The Cleveland Clinic Foundation
ACTIVE_NOT_RECRUITINGCleveland, Ohio, 44195, United States
-
The Ohio State University Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGColumbus, Ohio, 43210, United States
-
The University of Texas MD Anderson Cancer Center
ACTIVE_NOT_RECRUITINGHouston, Texas, 77030-4009, United States
-
Tom Baker Cancer Center
ACTIVE_NOT_RECRUITINGCalgary, T2N 4N2, Canada
-
UMC Groningen
ACTIVE_NOT_RECRUITINGGroningen, 9713 GZ, Netherlands
-
Universitaetsklinikum Essen
ACTIVE_NOT_RECRUITINGEssen, 45147, Germany
-
Universitaetsklinikum Hamburg-Eppendorf
ACTIVE_NOT_RECRUITINGHamburg, 20246, Germany
-
Universitaetsmedizin Mannheim
ACTIVE_NOT_RECRUITINGMannheim, 68167, Germany
-
Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
ACTIVE_NOT_RECRUITINGMontreal, HIT 2M4, Canada
-
University College London Hospital
ACTIVE_NOT_RECRUITINGLondon, NW1 2PG, United Kingdom
-
University of Alabama at Birmingham
WITHDRAWNBirmingham, Alabama, 35249, United States
-
University of Arizona- Cancer Center
ACTIVE_NOT_RECRUITINGTucson, Arizona, 85719, United States
-
University of California, Los Angeles (UCLA)
ACTIVE_NOT_RECRUITINGLos Angeles, California, 90404, United States
-
University of California, San Diego (UCSD)
ACTIVE_NOT_RECRUITINGSan Diego, California, 92093, United States
-
University of California, San Francisco
ACTIVE_NOT_RECRUITINGSan Francisco, California, 94158, United States
-
University of Colorado Denver
ACTIVE_NOT_RECRUITINGDenver, Colorado, 80204, United States
-
University of Iowa Hospital and Clinics
ACTIVE_NOT_RECRUITINGIowa City, Iowa, 52242, United States
-
University of Kansas Cancer Center
ACTIVE_NOT_RECRUITINGKansas City, Kansas, 66160, United States
-
University of Miami - Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
-
University of Michigan Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Pittsburgh Medical Center - Hillman Cancer Center
ACTIVE_NOT_RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
University of Tennessee
WITHDRAWNKnoxville, Tennessee, 37920, United States
-
University of Toledo Medical Center
WITHDRAWNToledo, Ohio, 43614, United States
-
University of Wisconsin - Carbone Cancer Center
ACTIVE_NOT_RECRUITINGMadison, Wisconsin, 53705, United States
-
Vanderbilt University Medical Center
ACTIVE_NOT_RECRUITINGNashville, Tennessee, 37232, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63130, United States
-
lnstituto Nacional de Cancer - INCA
ACTIVE_NOT_RECRUITINGRio de Janeiro, 20.230-130, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug targets Sugar-Coated proteins on cancer cells
- Zapping a few growing tumors may keep breast cancer drugs working longer
- Can a platform trial match the right drug combo to each tumor?
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Can a new antibody outsmart advanced solid tumors?
- Tissue analysis may guide personalized cancer therapy